Biliary Tract Cancers Pipeline 2024 | Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMT bio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee's Pharmaceutical

DelveInsight's, "Biliary Tract Cancers Pipeline Insight 2024" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Biliary Tract Cancers Pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Biliary Tract Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Biliary Tract Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Biliary Tract Cancer Pipeline Report

* July 2024:- Merck Sharp & Dohme LLC- A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers. Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with chemotherapy can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery).
* July 2024:- Amgen- A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors. The primary objective of Part 3 of this study is to evaluate the efficacy of AMG 193 in adult participants with metastatic or locally advanced MTAP-null solid tumors.
* DelveInsight's Biliary Tract Cancer pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for treatment.
* The leading Biliary Tract Cancer Companies such as Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMT bio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee's Pharmaceutical Limited, Hoffmann-La Roche, Shanghai Miracogen Inc., Zymeworks Inc., Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, Threshold Pharmaceuticals, Leap Therapeutics, Hutchison Medipharma Limited, Array BioPharma, Redx Pharma Plc, Compass Therapeutics, Lee's Pharmaceutical Limited, and others.
* Promising Biliary Tract Cancer Therapies such as Nivolumab, Gemcitabine, and S-1, Gemcitabine, cisplatin, Pembrolizumab, Sargramostim, oxaliplatin, KN035 plus Gemcitabine & oxaliplatin , and others.

Stay ahead with the most recent pipeline outlook for Biliary Tract Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Biliary Tract Cancer Treatment Drugs [https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Biliary Tract Cancer Emerging Drugs Profile

MRG 002: Miracogen

MRG 002, is an antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. An open-label, single-arm, multi-center, phase II Clinical Study of MRG002 are conducted by Miracogen for the treatment of patients with HER2-positive unresectable, locally advanced or metastatic biliary tract cancer. MRG002 is administrated by an IV infusion of 2.6 mg/kg on Day 1 of every 3 weeks (21-day cycle).

Disitamab vedotin: Yantai Rongchang Pharmaceutical

Disitamab Vedotin is an antibody-drug conjugate with a drug structure consisting of three parts Anti-human epidermal growth factor receptor 2 extracellular domain (HER2 ECD) antibody; Linker (MC-Val-Cit-PAB, Linker); and Cytotoxic Monomethyl Auristatin E (Monomethyl Auristatin E, MMAE). This product is white to light yellow loose body, after reconstitution, it is colorless to light yellow clear liquid.

Envafolimab: Alphamab Oncology

Envafolimab is a PD-L1 single-domain antibody Fc fusion protein independently developed by Alphamab. Based on the unique design, Envafolimab has advantages in safety, convenience and compliance, and can be used for patients who are not suitable for intravenous infusion with a lower medical cost. On March 30, 2020, Alphamab, 3D Medicines and Simcere reached a three-way strategic collaboration. Alphamab, as the original research party, is responsible for production and quality, 3D Medicines is responsible for global clinical development in the field of oncology, registration and commercialization abroad, and Simcere is responsible for the exclusive commercial promotion of the product in mainland China.

DKN-01: Leap Therapeutics

DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein. DKK1 modulates the Wnt/Beta-catenin and PI3kinase/AKT signaling pathways and has an important role in promoting tumor proliferation, metastasis, angiogenesis, and in mediating an immune suppressive tumor microenvironment through enhancing the activity of myeloid-derived suppressor cells and downregulating NK cell ligands on tumor cells.

Explore groundbreaking therapies and clinical trials in the Biliary Tract Cancer Pipeline. Access DelveInsight's detailed report now! @ New Biliary Tract Cancer Drugs [https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Biliary Tract Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Intravenous
* Subcutaneous
* Oral
* Intramuscular

Products have been categorized under various Molecule types such as

* Monoclonal antibody
* Small molecule
* Peptide

Unveil the future of Biliary Tract Cancer treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Biliary Tract Cancer Market Drivers and Barriers [https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Biliary Tract Cancer Pipeline Report

* Coverage- Global
* Biliary Tract Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Biliary Tract Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Biliary Tract Cancer Companies- Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMT bio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee's Pharmaceutical Limited, Hoffmann-La Roche, Shanghai Miracogen Inc., Zymeworks Inc., Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, Threshold Pharmaceuticals, Leap Therapeutics, Hutchison Medipharma Limited, Array BioPharma, Redx Pharma Plc, Compass Therapeutics, Lee's Pharmaceutical Limited, and others
* Biliary Tract Cancer Therapies- Nivolumab, Gemcitabine, and S-1, Gemcitabine, cisplatin, Pembrolizumab, Sargramostim, oxaliplatin, KN035 plus Gemcitabine & oxaliplatin, and others.

Get the latest on Biliary Tract Cancer therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Biliary Tract Cancer Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Biliary Tract Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Biliary Tract Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Envafolimab: Alphamab Oncology
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II/III)
* SMT-NK: SMT bio Co., Ltd.
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* HA121-28: CSPC ZhongQi Pharmaceutical Technology
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* ZKAB001: Lee's Pharmaceutical Limited
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Biliary Tract Cancer Key Companies
* Biliary Tract Cancer Key Products
* Biliary Tract Cancer- Unmet Needs
* Biliary Tract Cancer- Market Drivers and Barriers
* Biliary Tract Cancer- Future Perspectives and Conclusion
* Biliary Tract Cancer Analyst Views
* Biliary Tract Cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=biliary-tract-cancers-pipeline-2024-yantai-rongchang-pharmaceutical-remegen-emd-serono-smt-bio-co-ltd-cspc-zhongqi-pharmaceutical-technology-co-ltd-innopharmax-inc-lees-pharmaceutical]
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/



This release was published on openPR.